

SUPPLEMENTARY TABLES, FIGURES AND MOVIES

Supplementary Table S1: The plasmids used for the construction and transfection


Plasmids	Description	Origin
pGLV3/H1/GFP/Puro	Plasmid construction	Genepharma, Shanghai, China
LV5/GFP/Puro	Plasmid construction	Genepharma, Shanghai, China
LV6/Puro	Plasmid construction	Genepharma, Shanghai, China
PG-P1-VSVG	Lenti-virus production	Genepharma, Shanghai, China
PG-P2-REV	Lenti-virus production	Genepharma, Shanghai, China
PG-P3-RRE	Lenti-virus production	Genepharma, Shanghai, China
pLVTHM	Plasmid construction	Addgene, Cambridge, MA
pWPXL	Plasmid construction	Addgene, Cambridge, MA
psPAX2	Lenti-virus production	Addgene, Cambridge, MA
pMD2.G	Lenti-virus production	Addgene, Cambridge, MA

Supplementary Table S2: The sequences of the oligonucleotides for plasmids construct


Name	Sequence
Lenti-shRNA-vector	L: 5'-GATCCGTTCTCCGAACGTGTCACGTTTCAAGAGAA
(for AGPAT9)	CGTGACACGTTCCGAGAAGCTTTTTTG-3'
	R: 5'-AATTCAAAAAAGTTCTCCGAACGTGTCACGTTCT
	CTTGAAACGTGACACGTTCCGAGAACG-3'
Lenti-shRNA1-AGPAT9	L: 5'-GATCCGGAACTCTGATCCAGTATATTTCAAGAGA
	ATATACTGGATCAGAGTTCCCTTTTTTG-3'
	R: 5'-AATTCAAAAAAGGGAAGTCTGATCCAGTATATTTCT
	CTTGAAATATACTGGATCAGAGTTCCCG-3'
Lenti-shRNA2-AGPAT9	L: 5'-GATCCGGAAAGTGGCCACAGATAATGTTCAAGAG
	ACATTATCTGTGGCCACTTTCCTTTTTTG-3'
	R: 5'-AATTCAAAAAAGGAAAGTGGCCACAGATAATGTC
	TCTTGAACATTATCTGTGGCCACTTTCG-3'
Lenti-shRNA3-AGPAT9	L: 5'-GATCCGGACCTGCCTAATTACCTTCATTCAAGAGA
	TGAAGGTAATTAGGCAGGTCCTTTTTTG-3'
	R: 5'-AATTCAAAAAAGGACCTGCCTAATTACCTTCATCT
	CTTGAATGAAGGTAATTAGGCAGGTCG-3'

(continued)


Name	Sequence
Lenti-shRNA4-AGPAT9	L: 5'-GATCCGGAGGAGAGAAGATAGGTATTTCAAGAGA ATACCTATCTTCTCTCCTCCTTTTTTG-3'
	R: 5'-AATTCAAAAAAGGAGGAGAGAAGATAGGTATTCT CTTGAAATACCTATCTTCTCTCCTCCG-3'
Lenti-LASS2	L: 5'- TATACGCGTATGCTCCAGACCTTGTA-3'
	R: 5'-GCTACTAGTTCAGTCATTCTTACGATGGT-3'
Lenti-shRNA-vector (for LASS2 or ATP6V0C)	L: 5'- CGCGTCCCCTTCTCCGAACGTGTCACGTTTCAAG AGAACGTGACACGTTCCGAGAATTTTTGGAAAT-3'
	R: 5'-CGATTTCCAAAAATTCTCCGAACGTGTCACGTT CTCTTGAAACGTGACACGTTCCGAGAAGGGGA-3'
Lenti-shRNA1-LASS2	L: 5'-CGCGTCCCCGGCCCAGTCTCCTCAAGAATTCAAG AGATTCTTGAGGAGACTGGGCCTTTTTGGAAAT-3'
	R: 5'-CGATTTCCAAAAAGGCCAGTCTCCTCAAGAA TCTCTTGAATTCTTGAGGAGACTGGGCCGGGGA-3'
Lenti-shRNA2-LASS2	L: 5'-CGCGTCCCCAGTATTGGTACTACATGATTTCAA GAGAATCATGTAGTACCAATACTTTTTGGAAAT-3'
	R: 5'-CGATTTCCAAAAAGTATTGGTACTACATGATT CTCTTGAAATCATGTAGTACCAATACTGGGGA-3'
Lenti-shRNA1-ATP6V0C	L: 5'-CGCGTCCCCTCGGCCTCTACGGTCTCATTCAAGA GAATGAGACCGTAGAGGCCGATTTTTGGAAAT-3'
	R: 5'-CGATTTCCAAAAATCGGCCTCTACGGTCTCATTC TCTTGAAATGAGACCGTAGAGGCCGAGGGGA-3'
Lenti-shRNA2-ATP6V0C	L: 5'- CGCGTCCCCGTCCATCATCCCAGTGGTCTTCAAG AGAGACCACTGGGATGATGGACTTTTTGGAAAT-3'
	R: 5'- CGATTTCCAAAAAGTCCATCATCCCAGTGGTC TCTCTTGAAGACCACTGGGATGATGGACGGGGA-3'




Supplementary Figure S1: Correlation analysis of *AGPAT9* expression and chemosensitivity. **A.** The relative mRNA levels of *AGPAT9* in drug-sensitive MCF7 and drug-resistant MCF7/ADR cells. **B.** The overexpression of *AGPAT9* in MCF7/ADR cells obviously decreased the IC₅₀ value for Dox. **C.** The cells were visualized by confocal microscopy after sequentially loaded with Dox and Hoechst 33342. Red fluorescence indicates Dox; blue fluorescence indicates nuclei. Scale bars: 5 µm (C).




Supplementary Figure S2: Overexpression of *AGPAT9* inhibited the migration of MCF7/ADR cells. The migration of cells into the wound was monitored in multiple wells using a CellVoyager CV1000 confocal scanner system. The images were acquired every hour for 32 hours (see Supplementary Movies S5 and S6). The images shown represent 0 hour **A**, **C**, and 32 hours **B**, **D**. The distance between the two edges of the scratch in the Lenti-*AGPAT9* well (**D**) was greater than that of the control (**B**).




Supplementary Figure S3: Effect of overexpression or knockdown of *AGPAT9* on the proliferation, migration and invasion abilities of Bcap-37 cells. Proliferation was monitored for 48 h in the xCELLigence DP system **A**. The cell index was measured every 30 minutes. The rate of change of cell index as a function of time was calculated as a measure of proliferation activity. **B**. The cell index at the end (48 hrs) is shown as a bar chart. Migration **C**, or invasion **E**, was monitored for 24 h or 48 h in the xCELLigence DP system. The cell index was measured every 15 minutes. The rate of change of cell index as a function of time was calculated as a measure of migration or invasion activity. The cell index at the end (24 hrs or 48 hrs) is shown as a bar chart **D, F**.




Supplementary Figure S4: Knockdown of *ATP6V0C* inhibited the migration of MDA-MB-231 cells. The migration of cells into the wound was monitored in multiple wells using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 35 hours (see Supplementary Movies S7 and S8). The images shown represent 0 hour **A, C**, and 35 hours **B, D**. The distance between the two edges of the scratch in the Lenti-shRNA-ATP6V0C well (**D**) was greater than that of the control (**B**).




Supplementary Movie S1: The migration of Lenti-vector (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 28 hours.




Supplementary Movie S2: The migration of Lenti-AGPAT9 (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 28 hours.




Supplementary Movie S3: The migration of Lenti-vector-GFP (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 35 hours.




Supplementary Movie S4: The migration of Lenti-AGPAT9-GFP (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 35 hours.




Supplementary Movie S5: The migration of Lenti-vector (MCF7/ADR) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every hour for 32 hours.



Supplementary Movie S6: The migration of Lenti-AGPAT9 (MCF7/ADR) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every hour for 32 hours.



Supplementary Movie S7: The migration of Lenti-shRNA-vector (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 35 hours.



Supplementary Movie S8: The migration of Lenti-shRNA-ATP6V0C (MDA-MB-231) cells into the wound was monitored using a CellVoyager CV1000 confocal scanner system. The images were acquired every 0.5 hour for 35 hours.